Somazina® (Citicoline) 100 mg/ml, 30 ml oral solution

  • $39.90
Sku: d69db46e8bc4
Ingredient: Citicoline


100 ml of solution contains the active substance - sodium citicoline 10.4500 (equivalent to citicoline) (10.0000)

excipients: liquid crystalline sorbitol 70%, glycerin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, glycerin formaldehyde, sodium citrate dihydrate, sodium saccharin, Ponso 4-R dye (E 124), strawberry essence 1487 -S-Lucta 50, potassium sorbate-free citric acid, % solution, purified water.

Pharmacological properties


When taken orally, the absorption of citicoline from the gastrointestinal tract (GIT) is almost complete. After administration, the concentration of choline in plasma increases significantly. Citicoline has practically the same bioavailability for oral and parenteral administration. The pharmaceutical product is metabolized in the intestine and in the liver to form choline and cytidine. Citicoline quickly reaches the brain tissue and is actively incorporated into cell membranes, cytoplasm and mitochondria, activating the activity of phospholipids.

Elimination of the drug is very slow. Only a small amount of the dose (less than 3%) is excreted in the urine (as metabolites and unchanged) and feces. Approximately 12% of the dose is excreted through the respiratory tract.

Citicoline stimulates the biosynthesis of structural phospholipids in the neuronal membrane. By this action, citicoline improves the functioning of such membrane structures as ion pumps and receptors, without the regulation of which it is impossible for the normal conduction of nerve impulses.

Due to the stabilizing effect on the membrane, citicoline exhibits decongestant properties and reduces cerebral edema.

Citicoline reduces the severity of symptoms associated with states of cerebral dysfunction due to various pathological processes (such as traumatic brain injury and acute cerebrovascular accident). Citicoline reduces the manifestations of cognitive, sensory and motor disorders associated with cerebral pathology.

Indications for use

Cerebral circulation disorders in the acute and rehabilitation periods:

- head injuries and their consequences
- cognitive, sensory, motor and neuropsychological disorders caused by degenerative and vascular disorders of the brain

Method of administration and dosage

1 ml of solution contains 100 mg, the recommended dose is from 500 mg to 2000 mg per day, depending on the severity of the condition.

Adults: 500 mg (5 ml) 3 times a day, taken with a dosing syringe: The drug can be taken undiluted or diluted in half a glass of water (100 ml), taken with meals or between meals.

After each dose, it is recommended to rinse the syringe with water.

The duration of the course of treatment is determined by the attending physician.

Side effects

Determination of the frequency of side effects is carried out in accordance with the following criteria: very often (? 1/10), often (? From 1/100 to <1/10), infrequently (? From 1/1000 to <1/100), rarely ( ≥ 1/10000 to <1/1000), very rare (<1/10000).

Very rarely

- hallucinations, agitation, insomnia, fever,
feeling of heat, tremors, chills
- headache and dizziness
- arterial hypertension and hypotension, shortness of breath
- hyperemia, urticaria, exanthema, pruritus, possible development
anaphylactic shock
- nausea, vomiting, diarrhea
- edema


- allergy to one of the components of the drug
- patients with increased tone of the parasympathetic nervous system (vagus nerve)
- hereditary fructose intolerance, glucose-galactose malabsorption

Drug interactions

Should not be used concomitantly with drugs containing meclofenoxate. Enhances the effect of levodopa.

Special instructions

Due to the presence of 4-R, methyl parahydroxybenzoate, propyl parahydroxybenzoate in the composition of Ponso, an allergic reaction may develop.

Application in pediatrics

The experience of use in children is limited: therefore, the drug can be prescribed only in cases where the expected therapeutic benefit outweighs any possible risk.

The drug contains sorbitol, so patients with rare hereditary problems of fructose intolerance should not be taken. May cause bronchial asthma, especially in patients allergic to acetylsalicylic acid.

Pregnancy and lactation

There is no relevant data on the use of citicoline in pregnant women. The drug should not be used during pregnancy unless clearly needed. The drug can be used when the expected positive effect outweighs the possible risk.

Features of the influence of the drug on the ability to drive a vehicle or potentially dangerous mechanisms

Does not affect.


Symptoms: increased side effects of the drug.
Treatment: symptomatic therapy.

Storage conditions

Store at a temperature not exceeding 30 ° C.
Do not freeze or refrigerate.
Keep out of the reach of children!

Shelf life - 3 years
Do not use after the expiration date.
Write a review
Related Products
Kyivmedpreparat (Ukraine)
Sedavit (20 tablets)
Laboratoires Biocodex (France)
Stresam® (Etifoxine, Exist) 50 mg, 60 capsules
Out Of Stock
Sopharma AD, owner reg. cert. Olaynpharm JSC, Latvia (Bulgaria)
NEIROMIDIN® (Ipidacrine) 15 mg/ml, 10 ampoules
GLIATILIN® (Alpha-GPC) 400 mg, 14 capsules
Grindeks (Latvia)
BETAMAX® (Sulpirid) 100 mg, 30 coated tablets
UCB Pharma (Belgium)
Keppra® 30s 1000 mg film-coated tablets
Egis (Hungary)
Lucetam® (Piracetam) 1 g/5 ml x 10 Vials